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ABSTRACT
Objective: To determine the period prevalence of IBS and comorbid depression among
individuals with irritable bowel syndrome (IBS) in multi-state Medicaid population, and to
assess the impact of comorbid depression on healthcare utilization and costs among individuals
with IBS enrolled in Fee-for-Service Medicaid program.

Methods: A retrospective cohort study was conducted using 2006-2008 Medicaid Analytic
Extract files for 39 states. Beneficiaries with IBS were identified based on any medical claims
for the disease. Beneficiaries with one or more medical claims for depression during the study
period were considered to have had comorbid depression. For each beneficiary, the first claim
for IBS in 2007 was considered as the index date. 12-month post index date all-cause and IBSrelated healthcare utilization and costs were computed for each of the four medical service
components – inpatient, outpatient, emergency room, and prescription drug. Generalized linear
models were used to assess the impact of comorbid depression on healthcare utilization and
costs.
Results: The period prevalence of IBS in the population was 4.4 per 1,000 Medicaid
beneficiaries. The period prevalence of comorbid depression among beneficiaries with IBS was
26.88%. Beneficiaries with IBS and depression had significantly greater all-cause and IBSrelated inpatient, IBS-related outpatient, all-cause emergency room, all-cause and IBS-related
prescription drug utilization, and IBS-related outpatient, all-cause and IBS-related emergency
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room, and all-cause and IBS-related prescription drug costs as compared to those without
depression.
Conclusion: Given the impact on healthcare use and costs, there is a need for better screening
and management of depression in this population.
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CHAPTER I
BACKGROUND
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INTRODUCTION
Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder that is characterized by
abdominal pain, bloating, and alternating bowel habits. Over the past few decades, the criteria
for IBS diagnosis has changed from being exclusion based to symptom based. The various
symptom based models that are in place for IBS diagnosis are Manning, Rome I, Rome II, and
Rome III criteria. Based on the symptoms of the disease, IBS can be divided into three subtypes
– IBS constipation-dominant (IBS-C), IBS diarrhea-dominant (IBS-D), and IBS alternating
between constipation and diarrhea or mixed IBS (IBS-M).
Among all gastrointestinal diseases, IBS has a very high frequency. At least one in ten
primary care visits and approximately one-fourth to one-half of gastroenterology referral visits
can be attributed to IBS (Talley, Zinsmeister, Van Dyke, C. A. R. O. L., & Melton, 1991). In the
United States (US), IBS prevalence varies based on the criteria used for determining disease and
the study population. Prevalence for IBS has been estimated to be as high as 20%, with the
general range of prevalence report to be 10-15% (Saito, Schoenfeld, & Locke III, 2002).
Irrespective of the criteria used, the prevalence for IBS also varies by its subtypes (Hungin,
Whorwell, Tack, & Mearin, 2003; Guilera, Balboa, & Mearin, 2005). The prevalence of IBS-M
has been reported to be four times that of IBS-C, and three times that of IBS-D (Hungin et al.,
2003). Prevalence is said to vary by demographic factors including age and gender. In a study
conducted by Drossman et al. (1993), IBS prevalence was observed to be higher among
2

individuals aged less than 45 years as compared to those aged 45 years and above. As per
gender, the prevalence of IBS has been reported to be 2-3 times as high among females as
compared to males (Drossman et al., 1993; Hahn, Saunders, & Maier, 1997; Thompson, Heaton,
Smyth, & Smyth, 2000).
IBS has a marked impact on healthcare use and costs, driven by the variability of disease
symptoms and uncertain nature of its diagnosis and treatment. In their study of healthcare
burden, Talley et al. (1995) found the healthcare costs among individuals with IBS to be 1.6
times higher than those without IBS. Similar results were observed by Levy et al. (2001), who
also found higher healthcare costs associated with IBS diagnosis. A systematic review of costof-illness for IBS in the US reported that direct medical cost for each individual with the disease
ranged from $1,500 to $7,500 approximately with outpatient, inpatient, and pharmacy
expenditures being the predominant drivers of cost (Nellesen, Yee, Chawla, Lewis, & Carson,
2013). Another systematic literature search of studies on the cost of IBS in the UK and US that
were published between 1991 and 2003 found the cost of disease to vary from around $350 to
approximately $9,000 annually for each individual afflicted with the disease (MaxionBergemann, Thielecke, Abel, & Bergemann, 2006). Besides causing considerable health and
economic burden, IBS also adversely impacts work productivity and increase in work
absenteeism (Leong et al., 2003).
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LITERATURE REVIEW
According to the American Gastroenterological Association, irritable bowel syndrome (IBS) is
defined as “a combination of chronic or recurrent GI symptoms not explained by structural or
biochemical abnormalities, which is attributed to the intestines and associated with symptoms of
pain and disturbed defecation and/or symptoms of bloatedness and distention” (American
Gastroenterological Association, 1997). IBS is associated with chronic, recurring abdominal
pain or unease due to alteration in bowel habit, or both, without any trace of structural anomalies
to explain these symptoms.
IBS Diagnosis and Subtypes
The diagnostic criteria for IBS has changed over the past few decades, from a system which used
various exclusion criteria to the use of symptom-based models such as Manning criteria, Rome I,
Rome II, and Rome III. The Manning criteria, developed in the 1970s, includes questions about
pain, and whether it is relieved by defecation, increase in frequency of stool at pain initiation,
looser stools at the origin of pain, explicit abdominal swelling, feeling of unfinished emptying,
and flow of mucus through rectum (Manning, Thompson, Heaton, & Morris, 1978). The Rome I
criteria, incorporated in 1990, embraced the majority of the Manning criteria. However, ensuing
factor analysis on the criteria revealed that the first three symptoms, namely relief of pain on
defecation, incidence of looser stools and increase in frequency of stools with pain, clustered
well together while the remaining symptoms did not (Heller, & Schuster, 1990; Talley, Boyce, &
Jones, 1998). These considerations were taken into account while framing the Rome II criteria,
4

established in 1999, along with recognition that the resultant pain may stem from hard stool as
well as loose stool (Thompson et al., 1999). The Rome III criteria framed in 2006, modified the
Rome II criteria by taking into account the fact that for a person to be identified with IBS, he or
she must have had feelings of abdominal pain at least 3 days per month in the preceding 3
months along with two of the three symptoms listed under Rome II (Longstreth et al., 2006).
Based on the symptoms of the disease, IBS can be divided into three subtypes – IBS
constipation-dominant (IBS-C), IBS diarrhea-dominant (IBS-D), and IBS alternating between
constipation and diarrhea (IBS-M). The Rome III criteria, which is reliant majorly on the
consistency of stool, identifies IBS-C as cases where patients have hard stools more than 25% of
the time and loose stools less than 25% of time. When patients experience loose stools more
than 25% and hard stools less than 25% of the time then they are classified as IBS-D. Patients
that experience both hard and loose stool more than 25% of the time are said to be afflicted with
IBS-M (Tillisch et al., 2005).
Prevalence and Incidence of IBS
Among all the diseases affecting the gastrointestinal tract, IBS is the most frequent.
Approximately one in ten primary care visits and up to one-half of gastroenterology referral
visits can be attributed to IBS (Talley et al., 1991). In the United States (US), IBS prevalence
varies based on the determination criteria and the study population amongst other factors.
Prevalence rates for IBS have been reported to vary between 3% and 20%, with most estimates
reported to be between 10% and 15% (Saito et al., 2002). This variation in prevalence rates can
be partly attributed to differences in the threshold criteria for the diagnosis of IBS. In a
population-based mail survey conducted by Saito et al. (2000), variation in threshold criteria for
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IBS diagnosis such as presence of two, three, and four or more Manning symptoms and recurring
abdominal pain yielded prevalence rates of 17.0, 12.8 and 8.7 per 100, respectively.
Variation in prevalence of IBS subtypes has been noted based on determination criteria
(Hungin et al., 2003; Guilera et al., 2005). When using the Rome criteria for IBS diagnosis
among individuals residing across eight countries in Europe, Hungin and colleagues (2003)
found the prevalence of IBS-A to be four times higher than IBS-C and three times higher than
IBS-D. In contrast, Talley and colleagues (1995) found similar prevalence of IBS-C, IBS-D, and
IBS-A (~5%) when using Manning criteria for case ascertainment in a US-based sample.
Studies have revealed difference in prevalence of IBS among males and females, with
prevalence reported to be roughly 2-3 times as high in the latter group as compared to the former
(Drossman et al., 1993; Hahn et al., 1997; Thompson et al., 2000). Variation in IBS prevalence
has also been reported. As per age, studies have found inconsistent results. Some have reported
higher prevalence of IBS among adolescents and young adults as compared to older age groups
(Drossman et al., 1993; Thompson et al., 2000). Others have noted the prevalence of IBS to
increase with age, with prevalence being 8% for those aged between 65 to 74 years and 12% for
those older having age greater than 85 years (Talley, O’Keefe, Zinsmeister, & Melton, 1992).
Unlike prevalence, it is difficult to measure the incidence of IBS considering that the
symptoms of IBS manifest slowly and that individuals do not always seek care for symptoms
associated with IBS. A population-based study in the US, based on data from two surveys
conducted on the same sample one-year apart estimated the incidence of IBS to be around 10%
(Cremonini, & Talley, 2005). However, when incidence was determined using physician-based
diagnosis in the same sample, a substantially lower incidence rate of 196 cases per 100,000

6

person-years was observed (Locke et al., 2004). In their systematic review of the incidence of
post-infectious IBS, Thabane and colleagues (2007) estimated an IBS incidence rate of 10%
among individuals with a history of acute gastrointestinal infection.
Healthcare Utilization and Costs of IBS
Driven by the variability of disease symptoms and uncertain nature of its diagnosis and
treatment, IBS has a marked impact on healthcare use and costs. When examining the medical
costs of IBS through a self-reported questionnaire, Talley and colleagues (1995) found the
healthcare costs to be 60% greater for individuals with IBS than a control group of individuals
without IBS. A recent study of a commercially insured sample of individuals with IBS-C found
the incremental all-cause healthcare spending associated with the disease to be ~$4,000 per
member per year, with almost 80% of the incremental spending attributable to medical services
(Doshi et al., 2014). Similar results have been observed in other studies, with higher outpatient
visits, more frequent inpatient stays, and greater medication prescriptions reported among
individuals with IBS as compared to those without IBS (Longstreth et al., 2003). A study
conducted on the cost of care for individuals with IBS enrolled in a health maintenance
organization found that the cost incurred towards healthcare for those with IBS was 1.5 times the
cost incurred for those without IBS. The study noted that barring hospitalization, all other aspects
of costs were greater for individuals with IBS as compared to those without the disease. The
study further noted that even though individuals with IBS recorded higher costs for lower GI
services, only one-third of the total cost difference between those with and without IBS could be
attributed to services related to lower GI (Levy et al., 2001). Studies have also revealed that
annual healthcare visits made for gastrointestinal and non-gastrointestinal issues to be
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significantly greater for individuals with IBS, as compared to those without IBS (Levy,
Whitehead, Von Korff, & Feld, 2000; Drossman et al., 1993).
The utilization of healthcare resources among individuals with IBS is chiefly associated
with serial diagnostic tests and invasive procedures and operations (American
Gastroenterological Association, 2001). In their multivariate analysis on the association between
IBS and surgical procedures in physician-diagnosed IBS patients, Longstreth and colleagues
(2004) found cholecystectomy rates to be thrice as great for individuals with IBS as compared to
those without IBS. Rates for appendectomy and hysterectomy were also twice as high among
individuals with IBS as compared to those without IBS. Further, back surgery rate were 50%
higher in IBS group as compared to those without IBS. When assessing colonoscopy utilization
in different clinical settings, Lieberman and colleagues (2005) found that almost one in every
four colonoscopy performed in individuals less than 50 years of age were attributable to IBS.
Healthcare use and spending among individuals with IBS is not only higher than those
without the disease, but also comparable or in some cases higher than individuals with other
chronic disorders. When examining the charges associated with IBS treatment and comparing
them to charges associated with asthma treatment, Ricci and colleagues (2000) found the
healthcare charges for the former to be comparable to later ($7,547 vs. $7,170 per patient per
year). However, unlike asthma where charges per patient varied based on severity of symptoms,
charges for individuals with IBS were uniform throughout the study period with slight increase
seen at the time of diagnosis. In their comparison of increase in total all-cause healthcare
charges from 12-month pre-to-post diagnosis between individuals with IBS-C and migraine
enrolled in managed care plan, Mitra and colleagues (2011) found individuals with IBS-C to
have significantly greater increase in total charges than those with migraine.
8

Though several studies have examined the healthcare utilization and costs associated with
IBS among commercial payers, the information on burden of this disease in Medicaid population
is limited. Medicaid is a joint federal-state program that provides health insurance to indigent
population in the US. In their study of healthcare utilization and cost assessment among
individuals with IBS enrolled in California and North Carolina Medicaid programs, Martin and
colleagues (2003) found ~50% higher healthcare costs among Medicaid recipients with IBS as
compared to a control group of individuals without IBS. Expenses associated with office visits
and prescription drugs contributed towards the cost differential between the two groups.
Another study conducted to look into the economic burden of treatment failure to the
Missouri Medicaid for individuals with IBS-C found that ineffectiveness of primary therapy for
IBS-C led to an additional cost of over $4,000 to Missouri Medicaid compared to patients who
responded to the initial therapy. Failure to respond to initial therapy resulted in higher healthcare
resource utilization and led to implementation of more cost-intensive therapies (Guerin et al.,
2014).
IBS and Comorbidities
Besides the underlying disorder, individuals with IBS seek care for other GI and extra-intestinal
complaints. Studies have revealed that IBS and gastroesophageal reflux disease (GERD) have a
higher frequency of occurrence in combination than expected. One study found half of all
individuals with IBS to have GERD (Kennedy, Jones, Hungin, O’flanagan, & Kelly, 1998). A
study conducted using the Nationwide Emergency Department Sample (NEDS) to examine the
risk of osteoporosis and osteoporosis-related fractures in individuals with IBS found a
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significantly greater risk of osteoporosis or related fractures in this group as compared with the
non-IBS control group (Stobaugh, Deepak, & Ehrenpreis, 2013).
Although the underlying etiology is unknown, individuals with IBS have been reported to
have a greater likelihood of developing other disorders like depression, fibromyalgia, and
migraine. In one study, almost one-third of individuals with IBS were reported to experience
symptoms similar to that of fibromyalgia (Sperber et al., 1999). Another study reported that
fibromyalgia was prevalent in 20% of individuals with IBS (Lubrano et al., 2001). In a study
conducted among individuals with IBS enrolled in a health maintenance organization, prevalence
of psychiatric disorders including depression, anxiety and somatoform disorders was reported to
be as high as 90% (Whitehead et al., 2007). A population-based study conducted in Sweden also
found individuals with IBS to have significantly more psychiatric distress compared to a control
population (Österberg et al., 2000). Estimates on the occurrence of comorbid psychiatric
disorders among individuals with IBS range between 54% and 94%. (Irwin, Falsetti, Lydiard, &
Ballenger, 1996; Lydiard, Fossey, Marsh, & Ballenger, 1993; Walker, Gelfand, Gelfand, &
Katon, 1995; Drossman et al., 1988). Studies have observed depression to be the most common
psychiatric disorder associated with IBS, followed by anxiety (Whitehead, Palsson, & Jones,
2002). A cohort study conducted in the UK, using data from 123 general practices in the
General Practice Research Database (GPRD) reported that patients with IBS have a significantly
greater frequency of comorbid anxiety and depression than the control group (Jones, Latinovic,
Charlton, & Gulliford, 2006).
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Study significance
Though studies have assessed the healthcare utilization and costs associated with IBS, the burden
of this disease in Medicaid population is not well understood. To date, only a couple of studies
have examined the healthcare use and costs associated with IBS in Medicaid population (Martin
et al., 2003; Guerin et al., 2014). In both studies, IBS diagnosis was found to be associated with
incremental healthcare burden. These studies provided useful information on the burden of IBS
in a vulnerable population; however, certain limitations associated with these studies limit their
usefulness. First, these studies used limited state Medicaid data, which restricted the
generalizability of their findings. Second, the study by Martin et al. (2003) was based on
Medicaid data from more than a decade ago. With the expansion of Medicaid program through
passage of the Patient Protection and Affordable Care Act (PPACA) in 2010, several million
new enrollees have been added. With increasing enrollment, it is expected that resource
utilization associated with chronic diseases including IBS will likely increase over the coming
years. As a result, more recent estimates of disease prevalence and healthcare burden would
assist policy makers in resource allocation decisions.
As noted in an earlier section, IBS is often accompanied by comorbidities including
depression, which can further complicate the disease profile and resource use in this population.
To date, no study has assessed the incremental healthcare utilization and cost impact of comorbid
depression among individuals with IBS.
Considering these gaps in the literature, the following objectives for the proposed study
have been developed:
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RESEARCH OBJECTIVES
Objective I – To determine the prevalence of IBS, and comorbid depression among individuals
with IBS in multi-state Medicaid population.

Considering that there are no estimates of IBS prevalence in Medicaid population, the proposed
study aims to bridge this important gap in the literature. Prevalence of IBS will be calculated
using multi-state Medicaid data. Further, prevalence will be calculated and reported by different
demographic categories. Moreover, there are no estimates of prevalence of comorbid depression
among individuals with IBS in multi-state Medicaid population. An estimate of comorbid
depression prevalence in this population will not only add to the body of knowledge about the
relationship between IBS and depression but also aid state Medicaid policy makers make health
policy decisions in this population of patients.
Research Questions for Objective I –
1. What is the prevalence of IBS in the Medicaid population?
2. What is the prevalence of comorbid depression among adults with IBS in the Medicaid
population?
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Objective II – To determine the incremental healthcare burden of comorbid depression among
individuals with IBS enrolled in Medicaid program.
Depression is one of the most common psychiatric comorbidities in individuals with IBS
(Whitehead et al., 2007; Drossman et al., 1988). Studies in other chronic diseases have
established the significant economic burden of comorbid depression, in terms of medical costs
and healthcare resource utilization. For example, a study using the Medical Expenditure Panel
Survey (MEPS) data, revealed that diabetes patients with comorbid depression had greater
utilization of ambulatory care services and significantly more prescription medication fills than
those without comorbid depression (Egede, Zheng, & Simpson, 2002). Another study that
looked into healthcare costs for diabetes and congestive heart failure patients enrolled in the feefor-service Medicare program, found individuals with comorbid depression to incur greater
healthcare costs than individuals without comorbid depression (Unützer et al., 2009).

Research Questions for Objective II –
1. To determine the healthcare resource utilization of individuals with IBS with versus
without comorbid depression
2. To determine the healthcare costs for individuals with IBS with versus without comorbid
depression

13

BIBLIOGRAPHY

14

American Gastroenterological Association. (1997). American Gastroenterological Association
medical position statement: Irritable bowel syndrome. Gastroenterology, 112, 2118-2119.
American Gastroenterological Association. (2001). The Burden of Gastrointestinal Diseases.
Bethesda, MD. American Gastroenterological Association Press.
Cremonini, F., & Talley, N. J. (2005). Irritable bowel syndrome: epidemiology, natural history,
health care seeking and emerging risk factors. Gastroenterology Clinics of North
America, 34(2), 189-204.
Doshi, J. A., Cai, Q., Buono, J. L., Spalding, W. M., Sarocco, P., Tan, H., & Carson, R. T.
(2014). Economic burden of irritable bowel syndrome with constipation: a retrospective
analysis of health care costs in a commercially insured population. J Manag Care
Pharm, 20(4), 382-90.
Drossman, D. A., Li, Z., Andruzzi, E., Temple, R. D., Talley, N. J., Thompson, W. G., ... &
Koch, G. G. (1993). US householder survey of functional gastrointestinal
disorders. Digestive diseases and sciences, 38(9), 1569-1580.
Drossman, D. A., McKee, D. C., Sandler, R. S., Mitchell, C. M., Cramer, E. M., Lowman, B. C.,
& Burger, A. L. (1988). Psychosocial factors in the irritable bowel syndrome. A multivariate
study of patients and nonpatients with irritable bowel syndrome. Gastroenterology, 95(3),
701-708.
Egede, L. E., Zheng, D., & Simpson, K. (2002). Comorbid depression is associated with
increased health care use and expenditures in individuals with diabetes. Diabetes care, 25(3),
464-470.
15

Guerin, A., Carson, R. T., Lewis, B., Yin, D., Kaminsky, M., & Wu, E. (2014). The economic
burden of treatment failure amongst patients with irritable bowel syndrome with constipation
or chronic constipation: a retrospective analysis of a Medicaid population. Journal of medical
economics, 17(8), 577-586.
Guilera, M., Balboa, A., & Mearin, F. (2005). Bowel habit subtypes and temporal patterns in
irritable bowel syndrome: systematic review. The American journal of
gastroenterology, 100(5), 1174-1184.
Hahn, B. A., Saunders, W. B., & Maier, W. C. (1997). Differences between individuals with
self-reported irritable bowel syndrome (IBS) and IBS-like symptoms. Digestive diseases and
sciences, 42(12), 2585-2590.
Heller, B. R., & Schuster, M. M. (1990). Existence of irritable bowel syndrome supported by
factor analysis of symptoms in two community samples. Gastroenterology, 96, 336-340.
Hungin, A. P. S., Whorwell, P. J., Tack, J., & Mearin, F. (2003). The prevalence, patterns and
impact of irritable bowel syndrome: an international survey of 40 000 subjects. Alimentary
pharmacology & therapeutics, 17(5), 643-650.
Irwin, C., Falsetti, S. A., Lydiard, R. B., & Ballenger, J. C. (1996). Comorbidity of posttraumatic
stress disorder and irritable bowel syndrome. Journal of Clinical Psychiatry.
Jones, R., Latinovic, R., Charlton, J., & Gulliford, M. (2006). Physical and psychological co‐
morbidity in irritable bowel syndrome: a matched cohort study using the General Practice
Research Database. Alimentary pharmacology & therapeutics, 24(5), 879-886.

16

Kennedy, T. M., Jones, R. H., Hungin, A. P. S., O’flanagan, H., & Kelly, P. (1998). Irritable
bowel syndrome, gastro-oesophageal reflux, and bronchial hyper-responsiveness in the
general population. Gut, 43(6), 770-774.
Leong, S. A., Barghout, V., Birnbaum, H. G., Thibeault, C. E., Ben-Hamadi, R., Frech, F., &
Ofman, J. J. (2003). The economic consequences of irritable bowel syndrome: a US
employer perspective. Archives of internal medicine,163(8), 929-935.
Levy, R. L., Von Korff, M., Whitehead, W. E., Stang, P., Saunders, K., Jhingran, P., ... & Feld,
A. D. (2001). Costs of care for irritable bowel syndrome patients in a health maintenance
organization. The American journal of gastroenterology, 96(11), 3122-3129.
Levy, R. L., Whitehead, W. E., Von Korff, M. R., & Feld, A. D. (2000). Intergenerational
transmission of gastrointestinal illness behavior. The American journal of
gastroenterology, 95(2), 451-456.
Lieberman, D. A., Holub, J., Eisen, G., Kraemer, D., & Morris, C. D. (2005). Utilization of
colonoscopy in the United States: results from a national consortium. Gastrointestinal
endoscopy, 62(6), 875-883.
Locke, G. 3., Yawn, B. P., Wollan, P. C., Melton, L. 3., Lydick, E., & Talley, N. J. (2004).
Incidence of a clinical diagnosis of the irritable bowel syndrome in a United States
population. Alimentary pharmacology & therapeutics, 19(9), 1025-1031.
Longstreth, G. F., & Yao, J. F. (2004). Irritable bowel syndrome and surgery: a multivariable
analysis. Gastroenterology, 126(7), 1665-1673.
Longstreth, G. F., Thompson, W. G., Chey, W. D., Houghton, L. A., Mearin, F., & Spiller, R. C.
(2006). Functional bowel disorders. Gastroenterology, 130(5), 1480-1491.

17

Longstreth, G. F., Wilson, A., Knight, K., Wong, J., Chiou, C. F., Barghout, V., ... & Ofman, J. J.
(2003). Irritable bowel syndrome, health care use, and costs: a US managed care
perspective. The American journal of gastroenterology,98(3), 600-607.
Lubrano, E., Iovino, P., Tremolaterra, F., Parsons, W. J., Ciacci, C., & Mazzacca, G. (2001).
Fibromyalgia in patients with irritable bowel syndrome.International journal of colorectal
disease, 16(4), 211-215.
Lydiard, R. B., Fossey, M. D., Marsh, W., & Ballenger, J. C. (1993). Prevalence of psychiatric
disorders in patients with irritable bowel syndrome.Psychosomatics, 34(3), 229-234.
Manning, A. P., Thompson, W. G., Heaton, K. W., & Morris, A. F. (1978). Towards positive
diagnosis of the irritable bowel. BMJ, 2(6138), 653-654.
Martin, B. C., Ganguly, R., Pannicker, S., Frech, F., & Barghout, V. (2003). Utilization patterns
and net direct medical cost to Medicaid of irritable bowel syndrome. Current Medical
Research and Opinion®, 19(8), 771-780.
Maxion-Bergemann, S., Thielecke, F., Abel, F., & Bergemann, R. (2006). Costs of irritable
bowel syndrome in the UK and US. Pharmacoeconomics, 24(1), 21-37.
Mitra, D., Davis, K. L., & Baran, R. W. (2011). All-cause health care charges among managed
care patients with constipation and comorbid irritable bowel syndrome. Postgraduate
medicine, 123(3), 122-132.
Nellesen, D., Yee, K., Chawla, A., Lewis, B. E., & Carson, R. T. (2013). A systematic review of
the economic and humanistic burden of illness in irritable bowel syndrome and chronic
constipation. J Manag Care Pharm, 19(9), 755-64.

18

Österberg, E., Blomquist, L., Krakau, I., Weinryb, R. M., Åsberg, M., & Hultcrantz, R. (2000). A
population study on irritable bowel syndrome and mental health. Scandinavian journal of
gastroenterology, 35(3), 264-268.
Ricci, J. F., Jhingran, P., McLaughlin, T., & Carter, E. G. (2000). Costs of care for irritable
bowel syndrome in managed care. JCOM-WAYNE PA-, 7(6), 23-34.
Saito, Y. A., Locke, G. R., Talley, N. J., Zinsmeister, A. R., Fett, S. L., & Melton, L. J. (2000). A
comparison of the Rome and Manning criteria for case identification in epidemiological
investigations of irritable bowel syndrome. The American journal of
gastroenterology, 95(10), 2816-2824.
Saito, Y. A., Schoenfeld, P., & Locke III, G. R. (2002). The epidemiology of irritable bowel
syndrome in North America: a systematic review. The American journal of
gastroenterology, 97(8), 1910-1915.
Sperber, A. D., Atzmon, Y., Neumann, L., Weisberg, I., Shalit, Y., Abu-Shakrah, M., ... &
Buskila, D. (1999). Fibromyalgia in the irritable bowel syndrome: studies of prevalence and
clinical implications. The American journal of gastroenterology, 94(12), 3541-3546.
Stobaugh, D. J., Deepak, P., & Ehrenpreis, E. D. (2013). Increased risk of osteoporosis-related
fractures in patients with irritable bowel syndrome.Osteoporosis International, 24(4), 11691175.
Talley, N. J., Boyce, P., & Jones, M. (1998). Identification of distinct upper and lower
gastrointestinal symptom groupings in an urban population. Gut, 42(5), 690-695.
Talley, N. J., Gabriel, S. E., Harmsen, W. S., Zinsmeister, A. R., & Evans, R. W. (1995).
Medical costs in community subjects with irritable bowel
syndrome.Gastroenterology, 109(6), 1736-1741.

19

Talley, N. J., O’Keefe, E. A., Zinsmeister, A. R., & Melton, L. J. (1992). Prevalence of
gastrointestinal symptoms in the elderly: a population-based study. Gastroenterology, 102(3),
895-901.
Talley, N. J., Zinsmeister, A. R., & Melton, L. J. (1995). Irritable bowel syndrome in a
community: symptom subgroups, risk factors, and health care utilization. American journal
of epidemiology, 142(1), 76-83.
Talley, N. J., Zinsmeister, A. R., Van Dyke, C. A. R. O. L., & Melton, L. J. (1991).
Epidemiology of colonic symptoms and the irritable bowel syndrome.
Gastroenterology, 101(4), 927-934.
Thabane, M., Kottachchi, D. T., & Marshall, J. K. (2007). Systematic review and meta‐analysis:
the incidence and prognosis of post‐infectious irritable bowel syndrome. Alimentary
pharmacology & therapeutics, 26(4), 535-544.
Thompson, W. G., Heaton, K. W., Smyth, G. T., & Smyth, C. (2000). Irritable bowel syndrome
in general practice: prevalence, characteristics, and referral. Gut, 46(1), 78-82.
Thompson, W. G., Longstreth, G. F., Drossman, D. A., Heaton, K. W., Irvine, E. J., & MüllerLissner, S. A. (1999). Functional bowel disorders and functional abdominal
pain. Gut, 45(suppl 2), II43-II47.
Tillisch, K., Labus, J. S., Naliboff, B. D., Bolus, R., Shetzline, M., Mayer, E. A., & Chang, L.
(2005). Characterization of the alternating bowel habit subtype in patients with irritable
bowel syndrome. The American journal of gastroenterology, 100(4), 896-904.
Unützer, J., Schoenbaum, M., Katon, W. J., Fan, M. Y., Pincus, H. A., Hogan, D., & Taylor, J.
(2009). Healthcare Costs Associated with Depression in Medically Ill Fee‐for‐Service
Medicare Participants. Journal of the American Geriatrics Society, 57(3), 506-510.

20

Walker, E. A., Gelfand, A. N., Gelfand, M. D., & Katon, W. J. (1995). Psychiatric diagnoses,
sexual and physical victimization, and disability in patients with irritable bowel syndrome or
inflammatory bowel disease.Psychological medicine, 25(06), 1259-1267.
Whitehead, W. E., Palsson, O. S., Levy, R. R., Feld, A. D., Turner, M., & Von Korff, M. (2007).
Comorbidity in irritable bowel syndrome. The American journal of
gastroenterology, 102(12), 2767-2776.
Whitehead, W. E., Palsson, O., & Jones, K. R. (2002). Systematic review of the comorbidity of
irritable bowel syndrome with other disorders: what are the causes and
implications? Gastroenterology, 122(4), 1140-1156.

21

CHAPTER II
METHODOLOGY

22

METHODS

For the purpose of this study, a retrospective, longitudinal, cohort study of the 2006-2008
Medicaid fee-for-service (FFS) claims database for 39 states was conducted. Approval was
taken from the University of Mississippi Institutional Review Board, following which a data use
agreement (DUA) was made with Center for Medicare and Medicaid Services (CMS) through
Research Data Assistance Center (ResDAC).

Data Source
Established in 1965, Medicaid is a joint federal-state funded healthcare program that provides
medical care insurance coverage to indigent people in the United States (US). Though Medicaid
benefits vary among states, these benefits typically cover costs associated with physician and
hospital visits, emergency room visits, and prescription drugs. The Center for Pharmaceutical
Marketing and Management (CPMM) at the University of Mississippi houses the Medicaid data
for 39 states. The 2006-2008 Medicaid Analytic Extract (MAX) files for 39 states (all states
except Alaska, Hawaii, Maine, Missouri, Montana, North Dakota, Pennsylvania, South Dakota,
Utah, Wisconsin, Wyoming, and District of Columbia) was used for the purpose of the study.
The MAX data comprises of -
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1)

The Personal Summary (PS) file, which contains demographic variables (e.g. date of
birth, gender, race), monthly enrollment status, utilization summary, and eligibility
information for each of the beneficiaries.

2)

The inpatient (IP) discharge level file contains detailed information about the enrollees’
utilization of inpatient services including International Classification of Diseases, ninth
revision, clinical modification (ICD-9-CM) diagnosis codes (a maximum of 10 fields of
diagnosis codes), current procedural terminology fourth edition (CPT-4) or healthcare
common procedure coding system (HCPCS) procedure codes (a maximum of 7 fields of
procedure codes), discharge status, length of stay, and amount paid.

3)

The prescription drug (PD) claims file has information regarding utilization of
prescription drugs including the date of prescription fill, national drug classification
(NDC) codes, days of supply, quantity supplied, and amount paid.

4)

The other therapy (OT) claims file contains records for physician services, lab and clinic
services, home health, hospice and premium payments. The outpatient hospital
institutional claims are also captured in this file. The claims comprise of information
about diagnosis codes, procedure codes, and date of service. The MAX OT file contains
two fields for diagnosis codes and one field for procedure codes.

To ensure privacy, de-identified data is made available to study researchers. A unique common
identifier will be used to link data files for study purposes.

Objective I
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Study Sample
The target population for this objective included recipients who were continuously enrolled in
Medicaid FFS program for a period of three years from 2006 to 2008, and were greater than or
equal to 18 years of age as of January 1, 2006 and less than 65 years of age as of December 31,
2008. Recipients with one or more claims for long-term care were excluded from study
analyses. Recipients aged 65 years and above were also excluded considering that Medicaid is
not the primary payer for these individuals. Recipients with irritable bowel syndrome (IBS)
were identified using the ICD-9-CM code 564.1. Identification of depression among recipients
with IBS was based on presence of one or more medical claims for depression (having ICD-9CM codes of 296.20, 296.21, 296.22, 296.23, 296.24, 296.25, 296.26, 296.30, 296.31, 296.32,
296.33, 296.34, 296.35, 296.36, 296.50, 296.51, 296.52, 296.53, 296.54, 296.55, 296.56, 296.60,
296.61, 296.62, 296.63, 296.64, 296.65, 296.66, 296.89, 298.0, 300.4, 309.1, or 311) in the
period between 2006 - 2008.
Moreover, the study also excluded recipients who might have had any claims, either
primary or secondary, for malignant neoplasm of digestive organs and peritoneum (having ICD9-CM codes of 150.0 – 150.5, 150.8 – 150.9, 151.0 – 151.6, 151.8 – 151.9, 152.0 – 152.3, 152.8
-152.9, 153.0 – 153.9, 154.0 – 154.3, 154.8, 155.0 – 155.2, 156.0 – 156.2, 156.8 – 156.9, 157.0 –
157.4, 157.8 – 157.9, 158.0, 158.8-158.9, 159.0 – 159.1, 159.8 – 159.9), inflammatory bowel
disease that comprises of Crohn’s disease, ulcerative colitis, intestinal vascular insufficiency, or
non-infectious enteritis and colitis (having ICD-9-CM codes of 555.xx to 558.xx), or
diverticulosis (having ICD-9-CM codes of 562.01 – 562.03, 562.11 – 562.13) since they can
confound diagnosis of IBS.
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Objective II
Study Sample
The target population for this objective included recipients who were continuously enrolled in
Medicaid FFS program for a period of three years from 2006 to 2008, and were greater than or
equal to 18 years of age as of January 1, 2006 and less than 65 years of age as of December 31,
2008. Recipients with one or more claims for long-term care were excluded from study
analyses. Recipients aged 65 years and above were also be excluded considering that Medicaid
is not the primary payer for these individuals. The study excluded recipients who might have
had any claims (between 2006-2008), either primary or secondary, for malignant neoplasm of
digestive organs and peritoneum (having ICD-9-CM codes of 150.0 – 150.5, 150.8 – 150.9,
151.0 – 151.6, 151.8 – 151.9, 152.0 – 152.3, 152.8 -152.9, 153.0 – 153.9, 154.0 – 154.3, 154.8,
155.0 – 155.2, 156.0 – 156.2, 156.8 – 156.9, 157.0 – 157.4, 157.8 – 157.9, 158.0, 158.8-158.9,
159.0 – 159.1, 159.8 – 159.9), inflammatory bowel disease that comprises of Crohn’s disease,
ulcerative colitis, intestinal vascular insufficiency, or non-infectious enteritis and colitis (having
ICD-9-CM codes of 555.xx to 558.xx), or diverticulosis (having ICD-9-CM codes of 562.01 –
562.03, 562.11 – 562.13) since they can confound diagnosis of IBS.
Recipients with irritable bowel syndrome (IBS) were identified using the ICD-9-CM
code 564.1 if they had at least one primary or secondary diagnosis claim for IBS in 2007, and the
first observed IBS claim was considered as the “index date”. Recipients with claims for IBS
were divided into two groups based on the presence of one or more medical claims for
depression (having ICD-9-CM codes of 296.20, 296.21, 296.22, 296.23, 296.24, 296.25, 296.26,
296.30, 296.31, 296.32, 296.33, 296.34, 296.35, 296.36, 296.50, 296.51, 296.52, 296.53, 296.54,
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296.55, 296.56, 296.60, 296.61, 296.62, 296.63, 296.64, 296.65, 296.66, 296.89, 298.0, 300.4,
309.1, or 311) in the period between 2006 - 2008. Based on this inclusion and exclusion criteria,
individuals with IBS were classified into two mutually exclusive groups of individuals with IBS
with comorbid depression (IBS with depression) and individuals with IBS without comorbid
depression (IBS without depression).
Study Measures
Healthcare Utilization and Costs
The 12-month post-index date all-cause healthcare resource utilization was gauged for the major
medical service components – inpatient hospital, emergency room (ER), hospital outpatient,
outpatient physician office, and prescription medications.
Similarly, IBS-related healthcare costs were also computed, with costs being divided into
four main categories - inpatient, outpatient, emergency room, and prescription drug. IBS-related
medical (inpatient, ER, and outpatient) costs were calculated based on the presence of any
primary medical claim for irritable colon. IBS-related prescription drug costs were computed
based on prescription claims for drugs that are typically used for symptoms of IBS. These
include antispasmodics, anxiolytics, bile sequestrants, diphenoxylate, laxatives, loperamide, nonsteroidal anti-inflammatory drugs, opioids, pro-motility agents, selective serotonin-reuptake
inhibitors, and tricyclic agents. The medical procedures that are usually employed for diagnosis
of IBS were considered while calculating the IBS-related healthcare costs. These procedures
include flexible sigmoidoscopy, colonoscopy, X-ray – radiography, computerized tomography
scan, lower-GI series – barium tests, EMA blood tests, lactose breath hydrogen tests, complete
blood counts, stool tests, and abdominal ultrasound.
27

Other Variables
Age was determined as of December 31 of each year (2006-2008) in order to ascertain eligibility
for inclusion each year. While assessing healthcare costs, charlson comorbidity index (CCI) was
included as a measure of case mix variation between recipients with IBS with depression and
IBS without depression. The D’Hoore adaptation of CCI was used in the study. CCI scores for
the two groups will be calculated for the 12-month pre-index period.
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DATA ANALYSIS
Objective I
Period prevalence rate among adults with IBS was calculated by dividing the number of unique
recipients with primary or secondary diagnosis of IBS to the number of eligible Medicaid
recipients for the period of 2006-2008, after imposing the inclusion and exclusion criteria. Rates
were stratified by demographic variables (age, race, state, and region of the country). Prevalence
has been reported as cases per 1,000 Medicaid recipients.
Period prevalence of comorbid depression among adults with IBS was determined by
dividing the number of unique recipients with claims for both IBS and depression to the total
number of unique recipients with claims for IBS in the multi-state Medicaid population.
Prevalence rates were stratified by demographic variables (age, race, state, and region of the
country). Prevalence has been reported in percentage.

Objective II
Means and standard deviation or frequency and percentages were used to depict the
characteristics of the recipients. All analyses were conducted using the Statistical Analysis
Software (SAS®) version 9.4 (SAS Institute, Cary, NC). P values < 0.05 will be considered for
statistical significance.
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For each of the medical service components – inpatient, outpatient, emergency room, and
prescription drugs, a generalized linear model (GLM) with an appropriate distribution and link
was used to determine the impact of comorbid depression on all-cause and IBS-specific
healthcare utilization among adults with IBS. Appropriate distribution (Gaussian, Poisson,
Gamma, Inverse Gaussian or Wald) of the dependent variable, number of health services used,
was determined with the help of a Modified Park test (Manning and Mullahy, 2001). The link
function of the model was determined using the Pregibon Link test (Pregibon, 1980). Based on
the results of these tests, poisson distribution and log link was chosen for the generalized linear
models. Since, there was a substantial proportion of zero values for the inpatient and emergency
room count variables, Vuong test (Vuong, 1989) was used to assess whether the zero inflated
poisson or the zero inflated negative binomial distributions should be used instead of the
standard poisson to account for zero-inflation or over dispersion. Based on the results of the
Vuong test, zero inflated negative binomial was chosen as the appropriate distribution for allcause inpatient, IBS-related inpatient, and all-cause emergency room utilization variables, and
zero-inflated poisson was chosen as the appropriate distribution for the IBS-related emergency
room utilization variable.
To assess the impact of comorbid depression on all-cause and IBS-related healthcare
costs among adults with IBS, a GLM with an appropriate distribution and link function were
employed. To ascertain appropriate distribution of the dependent variable, healthcare cost in this
case, a Modified Park test was conducted (Manning and Mullahy, 2001). The link function was
determined using Pregibon Link test (Pregibon, 1980). Based on the results of these tests,
gamma distribution and log link were chosen for each of the eight GLM models for healthcare
costs. Due to presence of zero values for costs for some recipients for inpatient and emergency
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room expenditures, these particular cost measures were estimated using the two-part model. The
first part of the model comprised of a logistic regression model to predict the probability of
observing non-zero costs and the second part of the model was a GLM with gamma distribution
and log link for recipients with non-zero costs. Multiplying the probability of non-zero cost from
the first part with the estimated costs from the second part gave us the final cost estimates. The
two part model is usually used when there are many zero values in the data, which is very
common in healthcare data. The model adjusts for the zero costs as well as the skewness
resulting from large cost values to give a reliable estimate of medical costs (Blough et al, 1999).
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ABSTRACT

Objective: To determine the period prevalence of IBS and comorbid depression among
individuals with irritable bowel syndrome (IBS) in multi-state Medicaid population, and to
assess the impact of comorbid depression on healthcare utilization and costs among individuals
with IBS enrolled in Fee-for-Service Medicaid program.

Methods: A retrospective cohort study was conducted using 2006-2008 Medicaid Analytic
Extract files for 39 states. Beneficiaries with IBS were identified based on any medical claims
for the disease. Beneficiaries with one or more medical claims for depression during the study
period were considered to have had comorbid depression. For each beneficiary, the first claim
for IBS in 2007 was considered as the index date. 12-month post index date all-cause and IBSrelated healthcare utilization and costs were computed for each of the four medical service
components – inpatient, outpatient, emergency room, and prescription drug. Generalized linear
models were used to assess the impact of comorbid depression on healthcare utilization and
costs.

Results: The period prevalence of IBS in the population was 4.4 per 1,000 Medicaid
beneficiaries. The period prevalence of comorbid depression among beneficiaries with IBS was
26.88%. Beneficiaries with IBS and depression had significantly greater all-cause and IBS36

related inpatient, IBS-related outpatient, all-cause emergency room, all-cause and IBS-related
prescription drug utilization, and IBS-related outpatient, all-cause and IBS-related emergency
room, and all-cause and IBS-related prescription drug costs as compared to those without
depression.

Conclusion: Given the impact on healthcare use and costs, there is a need for better screening
and management of depression in this population.
Keywords: irritable bowel syndrome, depression, healthcare use, healthcare cost, prevalence
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ECONOMIC BURDEN OF COMORBID DEPRESSION AMONG INDIVIDUALS WITH
IRRITABLE BOWEL SYNDROME ENROLLED IN FEE-FOR-SERVICE MEDICAID

Introduction
Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder that is characterized by
abdominal pain, bloating, and alternating bowel habits. Based on the symptoms of the disease,
IBS can be divided into three subtypes – IBS constipation-dominant (IBS-C), IBS diarrheadominant (IBS-D), and IBS alternating between constipation and diarrhea (IBS-M). Among all
gastrointestinal diseases, IBS has a very high frequency. At least one in ten primary care visits
and approximately one-fourth to one-half of gastroenterology referral visits can be attributed to
IBS.1
In the United States (US), IBS prevalence varies based on the criteria used for
determining disease and the study population. Prevalence for IBS has been estimated to be as
high as 20%.2 Irrespective of the criteria used, the prevalence for IBS also varies by its
subtypes.3,4 The prevalence of IBS-M has been reported to be four times that of IBS-C, and
three times that of IBS-D.3 Prevalence is said to vary by demographic factors including age and
gender. In a study conducted by Drossman and colleagues (1993), IBS prevalence was observed
to be higher among individuals aged less than 45 years as compared to those aged 45 years and
above.5 As per gender, the prevalence of IBS has been reported to be 2-3 times as high among
females as compared to males.5, 6, 7
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IBS has a marked impact on healthcare use and costs, driven by the variability of disease
symptoms and uncertain nature of its diagnosis and treatment. In their study of healthcare
burden, Talley et al. found the healthcare costs among individuals with IBS to be 1.6 times
higher than those without IBS.8 Similar results were observed by Levy et al. (2001), who also
found higher healthcare costs associated with IBS diagnosis.9 Besides causing considerable
health and economic burden, IBS also adversely impacts work productivity and increase in work
absenteeism.10
Though studies have assessed the healthcare utilization and costs associated with IBS, the
burden of this disease in Medicaid population is not well understood. To date, only a couple of
studies have examined the healthcare use and costs associated with IBS in Medicaid
population.11, 12 In both studies, IBS diagnosis was found to be associated with incremental
healthcare burden. These studies provided useful information on the burden of IBS in a
vulnerable population; however, certain limitations associated with these studies limit their
usefulness. First, these studies used limited state Medicaid data, which restricted the
generalizability of their findings. Second, the study by Martin et al. was based on Medicaid data
from more than a decade ago. With the expansion of Medicaid program through passage of the
Patient Protection and Affordable Care Act (PPACA) in 2010, several million new enrollees
have been added. With increasing enrollment, it is expected that resource utilization associated
with chronic diseases including IBS will likely increase over the coming years. As a result, more
recent estimates of disease prevalence and healthcare burden would assist policy makers in
resource allocation decisions. Estimates on the occurrence of comorbid psychiatric disorders
among individuals with IBS range between 54% and 94%.13, 14, 15 Studies have observed
depression to be the most common psychiatric disorder associated with IBS, followed by
39

anxiety.16 IBS is often accompanied by comorbidities including depression, which can further
complicate the disease profile and resource use in this population.
Studies in other chronic diseases have established the significant economic burden of
comorbid depression, in terms of medical costs and healthcare resource utilization. For example,
a study using the Medical Expenditure Panel Survey (MEPS) data, revealed that diabetes patients
with comorbid depression had greater utilization of ambulatory care services and significantly
more prescription medication fills than those without comorbid depression.17 Another study that
looked into healthcare costs for diabetes and congestive heart failure patients enrolled in the feefor-service Medicare program, found individuals with comorbid depression to incur greater
healthcare costs than individuals without comorbid depression.18
Study significance
Considering that there are no estimates of IBS prevalence in multi-state Medicaid population,
one of the objectives of the study was to estimate the prevalence of IBS in multi-state Medicaid
population. Moreover, given that there are no estimates of prevalence of comorbid depression
among individuals with IBS in multi-state Medicaid population, the study aimed to determine the
prevalence of comorbid depression among recipients with IBS in the multi-state Medicaid
population. Additionally, no previous study has assessed the incremental healthcare utilization
and cost impact of comorbid depression among individuals with IBS in this population. This
study aimed to estimate the impact of comorbid depression on healthcare utilization and
expenditures among individuals with IBS in the multi-state Medicaid population.
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Study Methodology
For the purpose of this study, a retrospective, longitudinal, cohort study of the 2006-2008
Medicaid fee-for-service (FFS) claims database for 39 states (Alabama, Arizona, Arkansas,
California, Colorado, Connecticut, Delaware, Florida, Georgia, Idaho, Illinois, Indiana, Iowa,
Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota,
Mississippi, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North
Carolina, Ohio, Oklahoma, Oregon, Rhode Island, South Carolina, Tennessee, Texas, Vermont,
Virginia, Washington, and West Virginia) was conducted. Approval was taken from the
University of Mississippi Institutional Review Board, following which a data use agreement
(DUA) was made with Center for Medicare and Medicaid Services (CMS) through Research
Data Assistance Center (ResDAC).
Data Source
Established in 1965, Medicaid is a joint federal-state funded healthcare program that provides
medical care insurance coverage to indigent people in the United States (US). Though Medicaid
benefits vary among states, these benefits typically cover costs associated with physician and
hospital visits, emergency room visits, and prescription drugs. The 2006-2008 Medicaid
Analytic Extract (MAX) files for 39 states was used for the purpose of the study. The MAX
data comprises of -
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1)

The Personal Summary (PS) file, which contains demographic variables (e.g. date of
birth, gender, race), monthly enrollment status, utilization summary, and eligibility
information for each of the beneficiaries.

2)

The inpatient (IP) discharge level file contains detailed information about the enrollees’
utilization of inpatient services including International Classification of Diseases, ninth
revision, clinical modification (ICD-9-CM) diagnosis codes (a maximum of 10 fields of
diagnosis codes), current procedural terminology fourth edition (CPT-4) or healthcare
common procedure coding system (HCPCS) procedure codes (a maximum of 7 fields of
procedure codes), discharge status, length of stay, and amount paid.

3)

The prescription drug (PD) claims file has information regarding utilization of
prescription drugs including the date of prescription fill, national drug classification
(NDC) codes, days of supply, quantity supplied, and amount paid.

4)

The other therapy (OT) claims file contains records for physician services, lab and clinic
services, home health, hospice and premium payments. The outpatient hospital
institutional claims are also captured in this file. The claims comprise of information
about diagnosis codes, procedure codes, and date of service. The MAX OT file contains
two fields for diagnosis codes and one field for procedure codes.

Study Sample
Determination of prevalence of IBS and comorbid depression among adults with IBS
The target population for this objective included recipients who were continuously enrolled in
Medicaid FFS program for a period of three years from 2006 to 2008, and were greater than or
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equal to 18 years of age as of January 1, 2006 and less than 65 years of age as of December 31,
2008. Recipients with one or more claims for long-term care were excluded from study
analyses. Recipients aged 65 years and above were also excluded considering that Medicaid is
not the primary payer for these individuals. Recipients with irritable bowel syndrome (IBS)
were identified using the ICD-9-CM code 564.1. Identification of depression among recipients
with IBS was based on presence of one or more medical claims for depression (having ICD-9CM codes of 296.20, 296.21, 296.22, 296.23, 296.24, 296.25, 296.26, 296.30, 296.31, 296.32,
296.33, 296.34, 296.35, 296.36, 296.50, 296.51, 296.52, 296.53, 296.54, 296.55, 296.56, 296.60,
296.61, 296.62, 296.63, 296.64, 296.65, 296.66, 296.89, 298.0, 300.4, 309.1, or 311) in the
period between 2006 - 2008.
Moreover, the study also excluded recipients who might have had any claims, either
primary or secondary, for malignant neoplasm of digestive organs and peritoneum (having ICD9-CM codes of 150.0 – 150.5, 150.8 – 150.9, 151.0 – 151.6, 151.8 – 151.9, 152.0 – 152.3, 152.8
-152.9, 153.0 – 153.9, 154.0 – 154.3, 154.8, 155.0 – 155.2, 156.0 – 156.2, 156.8 – 156.9, 157.0 –
157.4, 157.8 – 157.9, 158.0, 158.8-158.9, 159.0 – 159.1, 159.8 – 159.9), inflammatory bowel
disease that comprises of Crohn’s disease, ulcerative colitis, intestinal vascular insufficiency, or
non-infectious enteritis and colitis (having ICD-9-CM codes of 555.xx to 558.xx), or
diverticulosis (having ICD-9-CM codes of 562.01 – 562.03, 562.11 – 562.13) since they can
confound diagnosis of IBS.
Impact of comorbid depression on healthcare utilization and costs
The target population for this objective included recipients who were continuously enrolled in
Medicaid FFS program for a period of three years from 2006 to 2008, and were greater than or
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equal to 18 years of age as of January 1, 2006 and less than 65 years of age as of December 31,
2008. Recipients with one or more claims for long-term care were excluded from study
analyses. Recipients aged 65 years and above were also be excluded considering that Medicaid
is not the primary payer for these individuals. The study excluded recipients who might have
had any claims (between 2006-2008), either primary or secondary, for malignant neoplasm of
digestive organs and peritoneum (having ICD-9-CM codes of 150.0 – 150.5, 150.8 – 150.9,
151.0 – 151.6, 151.8 – 151.9, 152.0 – 152.3, 152.8 -152.9, 153.0 – 153.9, 154.0 – 154.3, 154.8,
155.0 – 155.2, 156.0 – 156.2, 156.8 – 156.9, 157.0 – 157.4, 157.8 – 157.9, 158.0, 158.8-158.9,
159.0 – 159.1, 159.8 – 159.9), inflammatory bowel disease that comprises of Crohn’s disease,
ulcerative colitis, intestinal vascular insufficiency, or non-infectious enteritis and colitis (having
ICD-9-CM codes of 555.xx to 558.xx), or diverticulosis (having ICD-9-CM codes of 562.01 –
562.03, 562.11 – 562.13) since they can confound diagnosis of IBS.
Recipients with irritable bowel syndrome (IBS) were identified using the ICD-9-CM
code 564.1 if they had at least one primary or secondary diagnosis claim for IBS in 2007, and the
first observed IBS claim was considered as the “index date”. Recipients with claims for IBS
were divided into two groups based on the presence of one or more medical claims for
depression (having ICD-9-CM codes of 296.20, 296.21, 296.22, 296.23, 296.24, 296.25, 296.26,
296.30, 296.31, 296.32, 296.33, 296.34, 296.35, 296.36, 296.50, 296.51, 296.52, 296.53, 296.54,
296.55, 296.56, 296.60, 296.61, 296.62, 296.63, 296.64, 296.65, 296.66, 296.89, 298.0, 300.4,
309.1, or 311) in the period between 2006 - 2008. Based on this inclusion and exclusion criteria,
individuals with IBS were classified into two mutually exclusive groups of individuals with IBS
with comorbid depression (IBS with depression) and individuals with IBS without comorbid
depression (IBS without depression).
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Study Measures
The 12-month post-index date all-cause healthcare resource utilization was gauged for the major
medical service components – inpatient hospital, emergency room (ER), hospital outpatient,
outpatient physician office, and prescription medications.
Similarly, IBS-related healthcare costs were also computed, with costs being divided into
four main categories - inpatient, outpatient, emergency room, and prescription drug. IBS-related
medical (inpatient, ER, and outpatient) utilization and costs were calculated based on the
presence of any primary medical claim for irritable colon. IBS-related prescription drug
utilization and costs were computed based on prescription claims for drugs that are typically used
for symptoms of IBS. These include antispasmodics, anxiolytics, bile sequestrants,
diphenoxylate, laxatives, loperamide, non-steroidal anti-inflammatory drugs, opioids, promotility agents, selective serotonin-reuptake inhibitors, and tricyclic agents. The medical
procedures that are usually employed for diagnosis of IBS were considered while calculating the
IBS-related healthcare utilization and costs. These procedures include flexible sigmoidoscopy,
colonoscopy, X-ray – radiography, computerized tomography scan, lower-GI series – barium
tests, EMA blood tests, lactose breath hydrogen tests, complete blood counts, stool tests, and
abdominal ultrasound.
Age was determined as of December 31 of each year (2006-2008) in order to ascertain
eligibility for inclusion each year. While assessing healthcare costs, charlson comorbidity index
(CCI) was included as a measure of case mix variation between recipients with IBS with
depression and IBS without depression. The D’Hoore adaptation of CCI was used in the study.
CCI scores for the two groups will be calculated for the 12-month pre-index period.
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Statistical Analysis
Period prevalence rate among adults with IBS was calculated by dividing the number of unique
recipients with primary or secondary diagnosis of IBS to the number of eligible Medicaid
recipients for the period of 2006-2008, after imposing the inclusion and exclusion criteria. Rates
were stratified by demographic variables (age, race, state, and region of the country). Prevalence
has been reported as cases per 1,000 Medicaid recipients.
Period prevalence of comorbid depression among adults with IBS was determined by
dividing the number of unique recipients with claims for both IBS and depression to the total
number of unique recipients with claims for IBS in the multi-state Medicaid population.
Prevalence rates were stratified by demographic variables (age, race, state, and region of the
country). Prevalence has been reported in percentage.
Means and standard deviation or frequency and percentages were used to depict the
characteristics of the recipients. All analyses were conducted using the Statistical Analysis
Software (SAS®) version 9.4 (SAS Institute, Cary, NC). P values < 0.05 will be considered for
statistical significance.
For each of the medical service components – inpatient, outpatient, emergency room, and
prescription drugs, a generalized linear model (GLM) with an appropriate distribution and link
was used to determine the impact of comorbid depression on all-cause and IBS-specific
healthcare utilization among adults with IBS. Appropriate distribution (Gaussian, Poisson,
Gamma, Inverse Gaussian or Wald) of the dependent variable, number of health services used,
was determined with the help of a Modified Park test.19 The link function of the model was
determined using the Pregibon Link test.20 Based on the results of these tests, poisson
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distribution and log link was chosen for the generalized linear models. Since, there was a
substantial proportion of zero values for the inpatient and emergency room count variables,
Vuong test21 was used to assess whether the zero inflated poisson or the zero inflated negative
binomial distributions should be used instead of the standard poisson to account for zeroinflation or over dispersion. Based on the results of the Vuong test, zero inflated negative
binomial was chosen as the appropriate distribution for all-cause inpatient, IBS-related inpatient,
and all-cause emergency room utilization variables, and zero-inflated poisson was chosen as the
appropriate distribution for the IBS-related emergency room utilization variable.
To assess the impact of comorbid depression on all-cause and IBS-related healthcare
costs among adults with IBS, a GLM with an appropriate distribution and link function were
employed. To ascertain appropriate distribution of the dependent variable, healthcare cost in this
case, a Modified Park test was conducted.19 The link function was determined using Pregibon
Link test.20 Based on the results of these tests, gamma distribution and log link were chosen for
each of the eight GLM models for healthcare costs. Due to presence of zero values for costs for
some recipients for inpatient and emergency room expenditures, these particular cost measures
were estimated using the two-part model. The first part of the model comprised of a logistic
regression model to predict the probability of observing non-zero costs and the second part of the
model was a GLM with gamma distribution and log link for recipients with non-zero costs.
Multiplying the probability of non-zero cost from the first part with the estimated costs from the
second part gave us the final cost estimates. The two part model is usually used when there are
many zero values in the data, which is very common in healthcare data. The model adjusts for
the zero costs as well as the skewness resulting from large cost values to give a reliable estimate
of medical costs.22
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Study results
Table 1. Demographic and baseline characteristics

Variables
Race, n (%)
Caucasians
African-Americans
Others
Region, n (%)
North-east
South
Mid-west
West
Gender, n (%)
Female
Male
Age, mean (sd)
CCI score, mean (sd)
Healthcare utilization, mean
(sd)
All-cause inpatient
IBS-related inpatient
All-cause outpatient
IBS-related outpatient
All-cause emergency
room
IBS-related emergency
room
All-cause prescription
drugs
IBS-related prescription
drugs
Healthcare cost, mean (sd)
All-cause inpatient
IBS-related inpatient
All-cause outpatient

IBS only group (n=1450)

IBS + Depression group
(n=533)

p-value
<0.001

994 (68.55)
142 (9.79)
314 (21.66)

444 (83.30)
45 (8.44)
44 (8.26)
<0.001

701 (48.34)
505 (34.83)
225 (15.52)
19 (1.31)

111 (20.83)
258 ( 48.41)
158 (29.64)
6 (1.13)
<0.001

1179 (81.31)
271 (18.69)
46.41 (10.82)
1.47 (1.95)

477 (89.49)
56 (10.51)
46.61 (11.81)
1.39 (1.72)

0.734
0.412

0.75 (1.74)
0.20 (0.57)
157.12 (212.77)
6.12 (16.92)
2.36 (4.79)

1.02 (2.21)
0.29 (0.65)
174.09 (207.36)
10.78 (65.29)
5.63 (8.92)

0.004
0.002
0.113
0.012
<0.001

0.04 (0.25)

0.08 (0.32)

0.026

82.74 (66.47)

102.53 (68.36)

<0.001

11.39 (12.11)

13.94 (11.12)

<0.001

5358.97 (16810.87)
1174.70 (4362.96)
16069.67 (27902.91)

5510.78 (15574.12)
1397.35 (3939.12)
13990.02 (20062.53)

0.856
0.302
0.115
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IBS-related outpatient
All-cause emergency
room
IBS-related emergency
room
All-cause prescription
drugs
IBS-related prescription
drugs

370.03 (2297.88)
257.06 (1118.35)

588.20 (3488.29)
832.23 (2108.03)

0.107
<0.001

6.16 (89.66)

14.08 (155.67)

0.16

7146.52 (7652.25)

7835.62 (7863.77)

0.078

477.78 (775.44)

528.80 (836.14)

0.204

A total of 1,983 IBS patients were included in the study (1,450 patients in the IBS only group
and 533 patients in the IBS and depression group). The mean age of patients in the IBS group
(46 ± 11) was similar to that of the patients in the IBS and depression group (47 ± 12). Patients
in the two groups had similar comorbidity scores (CCI score of 1.47 for the IBS only group and
1.39 for the IBS and depression group). Patients in the IBS and depression group had a
significantly greater proportion of females as compared to patients in the IBS only group (89.5%
vs 81.3%, P<0.001). Moreover, the two groups differed significantly on race and the region of
the country that they are from. Additionally, the IBS and depression group had a significantly
greater mean utilization of all-cause inpatient admissions, IBS-related inpatient admissions, IBSrelated outpatient visits, all-cause and IBS-related emergency room admissions, and all-cause
and IBS-related prescription drug fills than the IBS only group. (Table 1)

Prevalence of IBS among Medicaid beneficiaries across the 39 state Medicaid programs
Table 2. Prevalence of IBS in the Medicaid population

Unadjusted prevalence rate
Adjusted prevalence rates
Adjusting for region
North-east
South
Mid-west

Rate per 1,000 Medicaid beneficiaries
4.4

6.2
7.5
7.1
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West
Adjusting for race
Caucasians
African Americans
Others
Adjusting for gender
Female
Male
Adjusting for age
18-25
26-35
36-45
46-55
56-65

0.2
9.0
2.8
1.6
5.1
2.6
1.6
2.1
4.0
8.1
9.0

Out of 449,690 beneficiaries that were eligible for the study, 1,983 had a diagnosis of IBS. The
unadjusted prevalence rate of IBS in the Medicaid population was 4.4 per 1,000 Medicaid
beneficiaries. Adjusting for region, we found the prevalence rate of IBS to vary from 7.5 for
beneficiaries from the North-eastern states to 0.2 for beneficiaries from the Western states per
1,000 Medicaid beneficiaries (Table 2). Adjusting for race, we noticed that prevalence rates
varied based on race, with Caucasians having the highest prevalence of IBS (9.2 per 1,000
Medicaid beneficiaries). Gender-adjusted estimates of prevalence revealed that IBS prevalence
was twice as much in females as in males (5.1 vs 2.6, per 1,000 Medicaid beneficiaries).
Adjusting for age, we found that beneficiaries who were 46 years old or older had the greatest
prevalence of IBS (8.1 and 9.0 per 1,000 Medicaid beneficiaries for beneficiaries in the age
groups 46-55 and 56-65 respectively).

Prevalence of comorbid depression among Medicaid beneficiaries with IBS
Table 3. Prevalence of comorbid depression among beneficiaries with IBS
Prevalence rate (%)
26.88

Unadjusted prevalence
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Prevalence rate (%)
Adjusted prevalence
Adjusting for region
North-east
South
Mid-west
West
Adjusting for race
Caucasians
African Americans
Others
Adjusting for gender
Male
Female
Adjusting for age
18-25
26-35
36-45
46-55
56-65

13.67
33.81
41.25
24.00
30.88
24.06
12.29
17.13
28.80
23.08
24.25
31.38
28.55
23.40

Out of the 1,983 IBS patients that had been included in the study, 533 patients also had a
diagnosis of depression. The unadjusted prevalence of comorbid depression among beneficiaries
with IBS was 26.9% (Table 3). Adjusting for region, race, gender, and age we found that IBS
patients from the Mid-western states had the highest prevalence of comorbid depression (41.3%),
Caucasians had a higher prevalence of comorbid depression as compared to beneficiaries from
other races (30.9% vs 24.1% and 12.3%), females had a higher prevalence of comorbid
depression as compared to males (28.8% vs 17.1%), and beneficiaries in the 36-45 age group had
a higher prevalence of comorbid depression (31.4%) than beneficiaries in other age groups
(Table 3).

51

Impact of comorbid depression on healthcare utilization among beneficiaries with IBS
Table 4. Comparison of healthcare utilization among the two groups
Type of utilization

All-cause inpatient
IBS-specific inpatient
All-cause outpatient
IBS-specific
outpatient
All-cause ER
IBS-specific ER
All-cause
prescription drugs
IBS-specific
prescription drugs

IBS and depression group
IBS only group
P-value
95% Confidence Interval
95% Confidence Interval
Adjusted Mean Lower 95% CI Upper 95% CI Adjusted Mean Lower 95% CI Upper 95% CI
1.058
0.729
1.535
0.689
0.453
1.051
0.001
0.251
144.071

0.138
142.024

0.455
146.147

0.133
143.193

0.08
141.345

0.22
145.065

<0.0005
0.134

8.045
3.876
0.391

7.633
3.01
0.161

8.479
4.989
0.948

5.411
2.055
0.527

5.161
1.568
0.256

5.673
2.693
1.085

<0.0005
<0.0005
0.497

66.599

65.141

68.091

57.059

55.879

58.262

<0.0005

9.543

8.999

10.119

7.83

7.409

8.275

<0.0005

A comparison of mean healthcare utilization among beneficiaries with IBS and beneficiaries
with IBS and depression is presented in Table 4. After adjusting for age, gender, region, other
comorbidities, and race, patients with IBS and depression had more all-cause inpatient visits
(1.06 vs 0.69, P = 0.001), IBS-specific inpatient visits (0.25 vs 0.13, P<0.001), IBS-specific
outpatient visits (8.04 vs 5.41, P<0.001), and all-cause emergency room admissions (3.88 vs
2.06, P<0.001) than IBS patients without depression. Additionally, beneficiaries with IBS and
depression had more all-cause prescription fills (66.6 vs 57.1, P<0.001) and IBS-specific
prescription fills (9.54 vs 7.83, P<0.001) than their non-depressed counterparts. We did not find
any statistically significant differences between the two groups in the mean number of all-cause
outpatient visits and IBS-specific emergency room admissions.
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Impact of comorbid depression on healthcare costs among beneficiaries with IBS
Table 5. Comparison of healthcare costs among the two groups
Type of cost

All-cause inpatient
(in US $)
IBS-specific inpatient
(in US $)
All-cause outpatient
(in US $)
IBS-specific
outpatient (in US $)
All-cause ER (in US
$)
IBS-specific ER (in
US $)
All-cause prescription
drug (in US $)
IBS-specific
prescription drug (in
US $)

IBS and depression group
IBS only group
P-value
95% Confidence Interval
95% Confidence Interval
Adjusted Mean Lower 95% CI Upper 95% CI Adjusted Mean Lower 95% CI Upper 95% CI
4,833

3,776

6,187

3,316

2,602

4,226

0.284

1,060

771

1,457

685

498

942

0.736

14,468

12,322

16,987

16,000

13,900

18,417

0.105

608

506

730

448

385

521

<0.0005

403

318

511

142

115

175

<0.0005

13

7

23

3

2

5

<0.0005

4,738

4,104

5,469

4,168

3,674

4,728

0.011

347

282

426

291

242

351

0.016

A comparison of mean healthcare expenditures among individuals with IBS and individuals with
IBS and depression is shown in Table 5. After adjusting for covariates, we found that individuals
with IBS and depression incurred more expenditures on IBS-related outpatient visits ($608 vs
$448, P<0.001), all-cause emergency room admissions ($403 vs $142, P<0.001) and IBS-related
emergency room admissions ($13 vs $3, P<0.001) than those with IBS but without depression.
Moreover, individuals with IBS and depression had significantly higher all-cause prescription
drug cost ($4,738 vs $4,168, P=0.011) and IBS-related prescription drug cost ($347 vs $291, P =
0.016) than their non-depressed counterparts with IBS. We did not find statistically significant
differences in any other expenditure category.
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Discussion
To the best of our knowledge, this is the first study to report prevalence rates, prevalence of
comorbid depression, and the impact of depression on all-cause and IBS-specific inpatient,
outpatient, emergency room, and prescription drug utilization and costs among adults with IBS
using multi-state Medicaid claims data.
A total of 1,983 Medicaid beneficiaries had a diagnosis of IBS across the 39 state
Medicaid programs in the period between 2006 and 2008. The period prevalence rate of IBS was
4.4 per 1,000 Medicaid beneficiaries. Our IBS prevalence estimates are lower than the treated
prevalence rates seen in published literature.11 This can be due to several reasons. One, study
only included beneficiaries that were continuously enrolled in the Medicaid Fee-for-Service
program for the entire study period (2006-2008). Two, the study excluded Medicaid
beneficiaries that were enrolled in long term care or had dual eligibility in Medicaid and
Medicare. Our prevalence estimates are also much lower than the 10-15% estimated by
population-based surveys. This can be attributed to various methodological factors. It is not
possible to detect IBS cases that are not diagnosed, or are misdiagnosed or miscoded from a
claims-based analysis. Additionally, the study excluded beneficiaries with any claim for
malignant neoplasm of digestive organs and peritoneum, inflammatory bowel disease, or
diverticulosis. Moreover, it has been reported that majority of the patients with IBS do not seek
healthcare.23 These factors may have led to an underestimation of IBS prevalence rates in the
study.
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The prevalence of comorbid depression among beneficiaries with IBS across the 39 state
Medicaid programs between 2006 and 2008 was 26.9%. The prevalence of comorbid depression
was similar to those found in previous studies. A study by Thijssen et al.24 reported presence of
comorbid depression in 22% of IBS patients. Another study by Whitehead et al.25 found a 30.5%
prevalence of comorbid depression among IBS patients. Martin et al.11 noted a prevalence of
12% and 19.3% of comorbid depression in California and North Carolina state Medicaids.
Among each gender females with IBS had a greater prevalence of comorbid depression than
males with IBS. This finding is similar to that of the study by Thijssen et al.24 who reported a
higher prevalence of depressive symptoms among males with IBS than females with IBS.
No study has previously examined the impact of comorbid depression on healthcare
utilization and expenditures among individuals with IBS. This study assessed the impact of
comorbid depression on healthcare utilization and costs on each of the four major healthcare
service components – inpatient, outpatient, emergency room, and prescription drugs, in order to
help identify drivers of healthcare utilization and costs in this patient population. Beneficiaries
with depression had more all-cause and IBS-specific inpatient, IBS-specific outpatient, all-cause
emergency room, all-cause and IBS-specific prescription drug utilization than their nondepressed counterparts. This is similar to the results of previous studies that have looked at the
impact of comorbid depression on the general population and other chronic diseases. A study by
Egede et al.17 reported significantly greater office visits and prescription drug use for individuals
with depression as compared to those without depression in a cohort of diabetes patients.
Another study by Himmelhoch et al.26 that looked at the impact of comorbid depression on
emergency department and inpatient hospitalization utilization among Medicare beneficiaries
with chronic medical conditions noted that patients with depression were more than two times as
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likely to use emergency department and inpatient hospital services as compared to those without
depression.
Moreover, we found that beneficiaries with depression had more IBS-specific outpatient,
all-cause and IBS-specific emergency room, all-cause and IBS-specific prescription drug
expenditures than those without depression. This is similar to that found in previous studies with
comorbid depression. Egede et al.17 observed that diabetes patients with depression had
significantly more total healthcare and prescription drug expenditures than those without
depression. A study that examined healthcare costs associated with anxiety and depressive
disorders in primary care reported that primary care patients with anxiety or depressive disorders
had significantly greater healthcare costs than those without.27 Another study that compared
healthcare costs among depressed and non-depressed patients with either diabetes, congestive
heart failure or both in Fee-for-Service Medicare found significantly greater healthcare costs
associated with the depressed group as compared with the non-depressed group.18
The findings of this study not only supports previous studies with respect to the economic
burden of comorbid depression but also significantly adds to the knowledge base about the
relationship between IBS and comorbid depression. Based on the result of this study, it seems
that there is a need for better depression screening and management among adults with IBS.
This is of great importance considering the high prevalence of comorbid depression in this
population and the markedly greater healthcare utilization and expenditure associated with
depression. A study that assessed the efficacy of an intervention program geared towards
improving depression outcomes among patients with diabetes and comorbid depression found
that compared to the control group, the patients in the intervention group had significantly lower
healthcare costs and showed improvement in depression outcomes.28
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Limitations
This study has a few limitations. The identification of IBS and depression was based on ICD-9CM diagnostic codes, and incorrect coding of the codes may lead to biased study results. It has
been seen that only a small proportion of the individuals with IBS seek medical care. The fact
that only the more severe individuals with disease seek medical care, may have overestimated
the healthcare resource use and cost estimates borne out of the analysis. Moreover, inherent
limitations of studies using administrative claims databases apply to this study as well. Also, as
in all observational studies, claims regarding causation cannot be made. We cannot infer that the
increased healthcare utilization and expenditures among the depressed group was solely due to
depression. Additionally, Medicaid coverage differs from one state to another and disparities in
different state Medicaid coverage may have affected the results of this study. Finally, the results
of this study cannot be generalized beyond the Medicaid Fee-for-Service population.

Conclusion
This is the first study to have assessed the prevalence of IBS, prevalence of comorbid depression,
and the impact of comorbid depression on healthcare utilization and costs among adults with
IBS, enrolled across several state Medicaid programs. This is also the first study to look into the
economic burden of comorbid depression among adults with IBS. The results of this study show
that comorbid depression has a significant impact on healthcare utilization and costs among
individuals with IBS. Given the high prevalence of comorbid depression among individuals with
IBS and the significantly greater healthcare utilization and costs incurred by those with comorbid
depression as compared to the non-depressed group, there is an immediate need for improvement
in depression screening and management in this population.
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SUMMARY & CONCLUSIONS
To the best of our knowledge, this is the first study to report prevalence rates, prevalence of
comorbid depression, and the impact of depression on all-cause and Irritable Bowel Syndromespecific (IBS-specific) inpatient, outpatient, emergency room, and prescription drug utilization
and costs among adults with IBS using multi-state Medicaid claims data. This study showed that
not only did the beneficiaries with IBS in the multi state Medicaid population have a very high
prevalence of comorbid depression but also that beneficiaries with depression had more all-cause
and IBS-specific inpatient, IBS-specific outpatient, all-cause emergency room, all-cause and
IBS-specific prescription drug utilization than their non-depressed counterparts. Additionally,
the study found that beneficiaries with depression had more IBS-specific outpatient, all-cause
and IBS-specific emergency room, all-cause and IBS-specific prescription drug expenditures
than those without depression. This study significantly adds to the knowledge base about the
relationship between IBS and comorbid depression. Based on the result of this study, it seems
that there is a need for better depression screening and management among adults with IBS.
This is of great importance considering the high prevalence of comorbid depression in this
population and the markedly greater healthcare utilization and expenditure associated with
depression.
The results of this study show that comorbid depression has a significant impact on healthcare
utilization and costs among individuals with IBS. Given the high prevalence of comorbid
depression among individuals with IBS and the significantly greater healthcare utilization and
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costs incurred by those with comorbid depression as compared to the non-depressed group, there
is an immediate need for improvement in depression screening and management in this
population. Future studies should examine the association between comorbid depression and
healthcare utilization and costs among individuals with IBS in other populations to gain a better
understanding of the economic burden of comorbid depression among individuals with IBS.
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Table 1. Demographic and baseline characteristics

Variables
Race, n (%)
Caucasians
African-Americans
Others
Region, n (%)
North-east
South
Mid-west
West
Gender, n (%)
Female
Male
Age, mean (sd)
CCI score, mean (sd)
Healthcare utilization, mean
(sd)
All-cause inpatient
IBS-related inpatient
All-cause outpatient
IBS-related outpatient
All-cause emergency
room
IBS-related emergency
room
All-cause prescription
drugs
IBS-related prescription
drugs
Healthcare cost, mean (sd)
All-cause inpatient
IBS-related inpatient
All-cause outpatient

IBS only group (n=1450)

IBS + Depression group
(n=533)

p-value
<0.001

994 (68.55)
142 (9.79)
314 (21.66)

444 (83.30)
45 (8.44)
44 (8.26)
<0.001

701 (48.34)
505 (34.83)
225 (15.52)
19 (1.31)

111 (20.83)
258 ( 48.41)
158 (29.64)
6 (1.13)
<0.001

1179 (81.31)
271 (18.69)
46.41 (10.82)
1.47 (1.95)

477 (89.49)
56 (10.51)
46.61 (11.81)
1.39 (1.72)

0.734
0.412

0.75 (1.74)
0.20 (0.57)
157.12 (212.77)
6.12 (16.92)
2.36 (4.79)

1.02 (2.21)
0.29 (0.65)
174.09 (207.36)
10.78 (65.29)
5.63 (8.92)

0.004
0.002
0.113
0.012
<0.001

0.04 (0.25)

0.08 (0.32)

0.026

82.74 (66.47)

102.53 (68.36)

<0.001

11.39 (12.11)

13.94 (11.12)

<0.001

5358.97 (16810.87)
1174.70 (4362.96)
16069.67 (27902.91)

5510.78 (15574.12)
1397.35 (3939.12)
13990.02 (20062.53)

0.856
0.302
0.115
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IBS-related outpatient
All-cause emergency
room
IBS-related emergency
room
All-cause prescription
drugs
IBS-related prescription
drugs

370.03 (2297.88)
257.06 (1118.35)

588.20 (3488.29)
832.23 (2108.03)

0.107
<0.001

6.16 (89.66)

14.08 (155.67)

0.16

7146.52 (7652.25)

7835.62 (7863.77)

0.078

477.78 (775.44)

528.80 (836.14)

0.204

Table 2. Prevalence of IBS in the Medicaid population

Unadjusted prevalence rate
Adjusted prevalence rates
Adjusting for region
North-east
South
Mid-west
West
Adjusting for race
Caucasians
African Americans
Others
Adjusting for gender
Female
Male
Adjusting for age
18-25
26-35
36-45
46-55
56-65

Rate per 1,000 Medicaid beneficiaries
4.4

6.2
7.5
7.1
0.2
9.0
2.8
1.6
5.1
2.6
1.6
2.1
4.0
8.1
9.0

70

Table 3. Prevalence of comorbid depression among beneficiaries with IBS
Prevalence rate (%)
26.88

Unadjusted prevalence
Adjusted prevalence
Adjusting for region
North-east
South
Mid-west
West
Adjusting for race
Caucasians
African Americans
Others
Adjusting for gender
Male
Female
Adjusting for age
18-25
26-35
36-45
46-55
56-65

13.67
33.81
41.25
24.00
30.88
24.06
12.29
17.13
28.80
23.08
24.25
31.38
28.55
23.40
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Table 4. Comparison of healthcare utilization among the two groups
Type of utilization

All-cause inpatient
IBS-specific inpatient
All-cause outpatient
IBS-specific
outpatient
All-cause ER
IBS-specific ER
All-cause
prescription drugs
IBS-specific
prescription drugs

IBS and depression group
IBS only group
P-value
95% Confidence Interval
95% Confidence Interval
Adjusted Mean Lower 95% CI Upper 95% CI Adjusted Mean Lower 95% CI Upper 95% CI
1.058
0.729
1.535
0.689
0.453
1.051
0.001
0.251
144.071

0.138
142.024

0.455
146.147

0.133
143.193

0.08
141.345

0.22
145.065

<0.0005
0.134

8.045
3.876
0.391

7.633
3.01
0.161

8.479
4.989
0.948

5.411
2.055
0.527

5.161
1.568
0.256

5.673
2.693
1.085

<0.0005
<0.0005
0.497

66.599

65.141

68.091

57.059

55.879

58.262

<0.0005

9.543

8.999

10.119

7.83

7.409

8.275

<0.0005
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Table 5. Comparison of healthcare costs among the two groups
Type of cost

All-cause inpatient
(in US $)
IBS-specific inpatient
(in US $)
All-cause outpatient
(in US $)
IBS-specific
outpatient (in US $)
All-cause ER (in US
$)
IBS-specific ER (in
US $)
All-cause prescription
drug (in US $)
IBS-specific
prescription drug (in
US $)

IBS and depression group
IBS only group
P-value
95% Confidence Interval
95% Confidence Interval
Adjusted Mean Lower 95% CI Upper 95% CI Adjusted Mean Lower 95% CI Upper 95% CI
4,833

3,776

6,187

3,316

2,602

4,226

0.284

1,060

771

1,457

685

498

942

0.736

14,468

12,322

16,987

16,000

13,900

18,417

0.105

608

506

730

448

385

521

<0.0005

403

318

511

142

115

175

<0.0005

13

7

23

3

2

5

<0.0005

4,738

4,104

5,469

4,168

3,674

4,728

0.011

347

282

426

291

242

351

0.016
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